This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
AdaptHealth Corp. (AHCO) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -96.77% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -3.85% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AdaptHealth Corp. (AHCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
AdaptHealth Corp. (AHCO) Misses Q3 Earnings Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -64.52% and 2.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
Company News for Aug 10, 2022
by Zacks Equity Research
Companies in The News Are: NEO,H,ARMK,AHCO
AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -35.71% and 0.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Surges 8.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CytoSorbents (CTSO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytoSorbents (CTSO) delivered earnings and revenue surprises of -78.57% and 11.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -109.52% and 9.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Akerna Corp. (KERN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akerna Corp. (KERN) delivered earnings and revenue surprises of -17.65% and 16.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Q4 Earnings Miss Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AdaptHealth Corp. (AHCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AdaptHealth Corp. (AHCO) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phillips (PHG) Blends 3D Mapping With Zenition, Aids Prospects
by Zacks Equity Research
Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AdaptHealth Corp. (AHCO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. LMAT: Which Stock Is the Better Value Option?
AHCO vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. SYK: Which Stock Is the Better Value Option?